Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020 Medical Dialogues Bureau26 Nov 2019 9:28 AM ISTRoche, whose drug Risdiplam is seen as a rival for Biogen's Spinraza and Novartis's Zolgensma gene therapy, said the FDA is due to decide by May 24....
